Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The higher potential efficacy of alpha-particle radiopharmaceutical therapy lies in the 3- to 8-fold greater relative biological effectiveness (RBE) of alpha particles relative to photon or beta-particle radiation. This greater RBE, however, also applies to normal tissue, thereby reducing the potential advantage of high RBE. As alpha particles typically cause DNA double-strand breaks (DSB), targeting tumors that are defective in DSB repair effectively increases the RBE, yielding a secondary, RBE-based differentiation between tumor and normal tissue that is complementary to conventional, receptor-mediated tumor targeting. In some triple-negative breast cancers (TNBC; ER−/PR−/HER-2−), germline mutation in BRCA-1, a key gene in homologous recombination DSB repair, predisposes patients to early onset of breast cancer. These patients have few treatment options once the cancer has metastasized. In this study, we investigated the efficacy of alpha-particle emitter, 213Bi-labeled anti-EGF receptor antibody, cetuximab, in BRCA-1–defective TNBC. 213Bi-cetuximab was found to be significantly more effective in the BRCA-1–mutated TNBC cell line HCC1937 than BRCA-1–competent TNBC cell MDA-MB-231. siRNA knockdown of BRCA-1 or DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), a key gene in non–homologous end-joining DSB repair pathway, also sensitized TNBC cells to 213Bi-cetuximab. Furthermore, the small-molecule inhibitor of DNA-PKcs, NU7441, sensitized BRCA-1–competent TNBC cells to alpha-particle radiation. Immunofluorescent staining of γ-H2AX foci and comet assay confirmed that enhanced RBE is caused by impaired DSB repair. These data offer a novel strategy for enhancing conventional receptor-mediated targeting with an additional, potentially synergistic radiobiological targeting that could be applied to TNBC. Mol Cancer Ther; 12(10); 2043–54. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“Few clinical trials have been launched partially due to the prevalent expression of EGFR on normal epithelial cells that lead to skin and gastrointestinal toxicity observed in cetuximab trials (43).”
BackgroundIniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Production of Ac-225 from Th-229 for Targeted α Therapy
Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215 · cited 3×
“225Ac was provided by the Institute forTransuraniumElements (Karlsruhe,Germany; refs.”
Self-citationAn Improved Method for the Production of Ac-225/Bi-213 from Th-229 for Targeted Alpha Therapy.
Zielinska, B., Apostolidis, C., Bruchertseifer, F., & Morgenstern, A. (2007) · Solvent Extraction and Ion Exchange · doi:10.1080/07366290701285108 · Cited by 100 · cited 3×
“225Ac was provided by the Institute forTransuraniumElements (Karlsruhe,Germany; refs.”
Self-citationBillecke, C. A., Ljungman, M. E., McKay, B. C., Rehemtulla, A., Taneja, N., & Ethier, S. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205546 · Cited by 28
Cited by
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
Bismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
Combination Strategies to Improve Targeted Radionuclide Therapy
Chan, T. G., O’Neill, E., Habjan, C., & Cornelissen, B. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.248062 · Cited by 91
“These combination studies are mainly with EBRT (32–34), but there are a few examples showing their ability to also radiosensitize TRT (35,36); however, it remains to be seen how these TRT combinations perform clinically.”
BackgroundSgouros, G. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.11.002 · Cited by 60
Self-citation
Metadata
- Authors
- Song, H., Hedayati, M., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., DeWeese, T. L., & Sgouros, G.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-10-01
- Volume
- 12
- Issue
- 10
- Pages
- 2043-2054
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2161837289
- Cited by
- 48
- References
- 5
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0108
- The paper
- Song, H., Hedayati, M., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., DeWeese, T. L., & Sgouros, G. (2013). Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.